Navigation Links
Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
Date:4/12/2013

SOUTH SAN FRANCISCO, Calif., April 12, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Shelly D. Guyer as chief financial officer.

"We are delighted to welcome Shelly Guyer to the Veracyte team," said Bonnie Anderson , Veracyte's cofounder and chief executive officer. "Her extensive background in the life science and finance industries will be critical as we experience strong growth of our first product, the Afirma® Thyroid FNA Analysis, and as we expand our molecular cytology platform to other clinical areas to similarly help reduce unnecessary surgeries and lower healthcare costs." Ms. Anderson noted that data published in the New England Journal of Medicine suggest that Veracyte's genomic test for improved thyroid cancer diagnosis can potentially help tens of thousands of patients each year in the United States avoid thyroid surgery.

Ms. Guyer previously was chief financial officer and executive vice president of finance and administration at iRhythm Technologies, a private, venture-backed medical device and services company. Prior to that, she served on the management team and as vice president of business development and investor relations at Nuvelo, a public biotechnology company. Ms. Guyer began her business career at J.P. Morgan Securities and its predecessor companies, where for over 17 years she held various positions, including principal and vice president of health care banking for the West Coast, leading financings for a variety of large and small cap life science companies.

"I am pleased to join the talented management team at Veracyte," said Ms. Guyer. "The company's mission of helping patients avoid surgery is compelling.
'/>"/>

SOURCE Veracyte, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
2. Veracyte Appoints Mark Spring as Chief Financial Officer
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 Emerson Ecologics is ... The Business of Better Medicine . The conference will ... to develop a thriving and fulfilling practice. ... La Costa Resort and Spa, the conference will be ... expect to accomplish key projects and leave with an ...
(Date:4/1/2015)... 2015  VLP Therapeutics, LLC. ("VLP"), a ... and development of therapeutic and preventative vaccines and next ... vaccine technology, today announced that it has entered into a ... Nagasaki University in ... and development of dengue vaccine candidates. ...
(Date:4/1/2015)... Goldman Small Cap Research, a stock market ... sectors, announced today that it has issued a new ... publicly traded clinical stage biotechnology company focused on developing ... the sponsored research article, along with disclosures and disclaimers, ... www.GoldmanResearch.com .  In the article ...
(Date:4/1/2015)... -- EMD Serono, the U.S. biopharmaceuticals subsidiary of Merck KGaA, ... appointment of Frederick E. Munschauer to Vice ... capacity, he will lead the medical affairs activities for ... Rebif ® (interferon beta-1a) as well as the ... Munschauer joins EMD Serono from Biogen, bringing more than ...
Breaking Biology Technology:Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5
... Calif., Dec. 21 2010 El Camino Hospital today ... U.S. Clinical Trial. El Camino Hospital is one of ... participate in the trial, which is evaluating a revolutionary ... surgery for patients with severe aortic stenosis. ...
... that a new market research report is available in its ... and companies http://www.reportlinker.com/p0203543/Gene-Therapy---technologies-markets-and-companies.html ... on gene therapy with 72 tables and 13 figures ... 700 selected references from the literature - Estimates ...
... NEW YORK, Dec. 21, 2010 Reportlinker.com announces ... in its catalogue: Nanobiotechnologies- applications, ... SummaryNanotechnology is the creation ... the control of matter on the nanometer-length scale ...
Cached Biology Technology:El Camino Hospital Announces First Implant in Clinical Trial to Evaluate Revolutionary Heart Valve Procedure 2El Camino Hospital Announces First Implant in Clinical Trial to Evaluate Revolutionary Heart Valve Procedure 3Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Reportlinker Adds Nanobiotechnologies- applications, markets and companies 2Reportlinker Adds Nanobiotechnologies- applications, markets and companies 3Reportlinker Adds Nanobiotechnologies- applications, markets and companies 4Reportlinker Adds Nanobiotechnologies- applications, markets and companies 5Reportlinker Adds Nanobiotechnologies- applications, markets and companies 6Reportlinker Adds Nanobiotechnologies- applications, markets and companies 7Reportlinker Adds Nanobiotechnologies- applications, markets and companies 8Reportlinker Adds Nanobiotechnologies- applications, markets and companies 9Reportlinker Adds Nanobiotechnologies- applications, markets and companies 10Reportlinker Adds Nanobiotechnologies- applications, markets and companies 11Reportlinker Adds Nanobiotechnologies- applications, markets and companies 12Reportlinker Adds Nanobiotechnologies- applications, markets and companies 13Reportlinker Adds Nanobiotechnologies- applications, markets and companies 14
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Blood clotting is a complicated business, particularly for those trying ... new study, researchers report that they are the first to ... to blood clotting. This interaction between a clotting factor ... The study appears online in the ...
... research team, with Spanish participation, has described two new ... (beetles) were found in streams in the Pyrenees and ... Sierra de la Demanda mountains (Burgos). Experts had previously ... "These species, which have a restricted range, had been ...
... Bethesda, MDIf you are one of the millions of people ... news is on the way. A new research discovery published ... ) offers hope for new drugs that treat the cellular ... the research is the first to identify natural killer (NK) ...
Cached Biology News:Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3New endemic beetles discovered in Iberian Peninsula 2Harvard scientists 'see' the early cellular cause of dry eye disease for the first time 2
Useful for determination of glucose and ATP. Packaging: Package sizes are based on hexokinase units. Preparation Unit Definition: One unit will phosphorylate 1.0 mol of D -glucose per min at pH ...
... form: Lyophilized powder containing ... Unit Definition: One unit ... 2-phosphoglycerate to phospho(enol)pyruvate per ... 25 C. Chem comp: ...
SCCRO (S-17)...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
Biology Products: